Last reviewed · How we verify
Alprostadil Injection
At a glance
| Generic name | Alprostadil Injection |
|---|---|
| Also known as | No other names |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE) (NA)
- A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (PHASE2)
- Anorectal Manometery in Pediatric Chronic Refractory Constipation (PHASE1, PHASE2)
- Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke (PHASE4)
- The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers (PHASE2)
- Radiological Evaluation of the Penis Before and After a Botox Injection (PHASE1, PHASE2)
- Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow (PHASE1)
- Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alprostadil Injection CI brief — competitive landscape report
- Alprostadil Injection updates RSS · CI watch RSS
- The Affiliated Hospital of Xuzhou Medical University portfolio CI